Published in Clin Ther on March 29, 2015
Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | NCT01629758
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | NCT01772004
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | NCT01975831
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN) | NCT01943461
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan | NCT00836888
Treatment of Advanced Melanoma With MK-3475 and Peginterferon | NCT02112032
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | NCT01386502
Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (PD-L1) | NCT01455103
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure (2015) 1.27
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer (2015) 1.07
The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) (2015) 1.06
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget (2016) 0.92
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci (2016) 0.85
A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology (2016) 0.82
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol (2015) 0.82
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. J Immunol Res (2015) 0.81
The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn (2015) 0.81
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology (2016) 0.81
Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med (2016) 0.80
Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Transl Oncol (2016) 0.79
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines. Medicine (Baltimore) (2016) 0.78
SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. Oncotarget (2016) 0.78
Immune Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer (2015) 0.77
PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. J Cancer (2015) 0.77
Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry. Int J Mol Sci (2016) 0.77
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) (2017) 0.76
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunol Res (2016) 0.76
Clinical implications of basic research in hepatocellular carcinoma. J Hepatol (2015) 0.76
Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget (2017) 0.76
Immune-Mediated Therapies for Liver Cancer. Genes (Basel) (2017) 0.75
Pembrolizumab in classical Hodgkin's lymphoma. Eur J Haematol (2016) 0.75
Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle. Front Immunol (2017) 0.75
A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. Clin Cancer Res (2016) 0.75
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. Am J Cancer Res (2016) 0.75
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. Liver Cancer (2016) 0.75
Acute Hyperglycemia Associated with Anti-Cancer Medication. Endocrinol Metab (Seoul) (2017) 0.75
A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) (2016) 0.75
Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy. JAAD Case Rep (2016) 0.75
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology (2016) 0.75
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Res Treat (2017) 0.75
Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination. Front Immunol (2016) 0.75
Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul. Cancer Immunol Res (2016) 0.75
A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer. Neuroophthalmology (2017) 0.75
Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol (2016) 0.75
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Transl Oncogenomics (2015) 0.75
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine (Baltimore) (2017) 0.75
Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model. Evid Based Complement Alternat Med (2017) 0.75
Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol (2016) 0.75
Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. Oncotarget (2016) 0.75
Focus on cutaneous and uveal melanoma specificities. Genes Dev (2017) 0.75
Intratumor and Intertumor Heterogeneity in Melanoma. Transl Oncol (2017) 0.75
Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Arch (2017) 0.75
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget (2017) 0.75
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy. Curr Radiol Rep (2017) 0.75
Basis for molecular diagnostics and immunotherapy for esophageal cancer. Expert Rev Anticancer Ther (2016) 0.75
Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. Intern Med (2017) 0.75
Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer. Oncol Lett (2017) 0.75
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab. J Blood Med (2017) 0.75
A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol (2017) 0.75
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. Transl Lung Cancer Res (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 14.39
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol (2003) 6.07
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer (2010) 5.05
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet (1999) 4.72
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2013) 3.74
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol (2010) 3.06
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol (2003) 2.91
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70
Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol (1996) 2.69
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med (2003) 2.65
Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity (2014) 2.58
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med (1997) 2.51
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A (2005) 2.49
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res (2014) 2.26
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol (2006) 2.15
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol (2004) 2.02
Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. J Immunol (2004) 1.91
Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp Cell Res (1997) 1.85
Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp Med (1999) 1.69
Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer (2010) 1.68
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol (2015) 1.68
Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun (2003) 1.49
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med (2013) 1.48
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell (2014) 1.45
Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol (1999) 1.44
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res (2013) 1.39
PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur J Immunol (2006) 1.38
Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) (2014) 1.29
Alternative splice variants of the human PD-1 gene. Cell Immunol (2005) 1.24
Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J Immunol (2010) 1.02
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer (2014) 1.01
Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc Natl Acad Sci U S A (2008) 1.00
B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). FEBS Lett (2005) 0.98
The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response. Immunogenetics (2012) 0.97
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother (2012) 0.86
A new therapeutic strategy for malaria: targeting T cell exhaustion. Nat Immunol (2012) 0.81